Solventum Corporation (BST:KB7)
Germany · Delayed Price · Currency is EUR | Market Cap | 12.08B +7.7% |
| Revenue (ttm) | 7.17B -0.6% |
| Net Income | 1.24B +277.8% |
| EPS | 7.08 +275.1% |
| Shares Out | n/a |
| PE Ratio | 9.72 |
| Forward PE | 11.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Open | 69.20 |
| Previous Close | 69.40 |
| Day's Range | 68.60 - 69.80 |
| 52-Week Range | 53.60 - 75.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Solventum
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tap... [Read more]
Financial Performance
In 2025, Solventum's revenue was $8.33 billion, an increase of 0.86% compared to the previous year's $8.25 billion. Earnings were $1.56 billion, an increase of 224.84%.
Financial numbers in USD Financial StatementsNews
Solventum Transcript: Jefferies Global Healthcare Conference 2026
The business is executing a three-phase transformation, focusing on innovation, portfolio optimization, and margin expansion. Strong Q1 results support higher-end EPS guidance, with ongoing product launches and AI integration driving growth. Capital allocation balances tuck-in M&A and share repurchases.
Solventum to Participate in the 2026 Jefferies Healthcare Conference
EAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026,...
Solventum Transcript: AGM 2026
Shareholders elected Class II directors, approved executive compensation, and ratified PwC as auditors with strong majorities. Quorum and proper notice were confirmed, and Q&A responses will be posted online.
Solventum Transcript: Bank of America Global Healthcare Conference 2026
Health Information Systems is experiencing accelerated growth through AI-driven automation, international expansion, and deep U.S. market penetration, with over 75% of hospitals using its products. The business maintains high margins, leverages proprietary rules for accuracy, and expects stable performance despite ERP-driven sales timing shifts.
Solventum to Participate in the 2026 BofA Securities Health Care Conference
ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May ...
Solventum forecasts annual profit at higher end on wound care demand
Medical device maker Solventum said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for its wound care and sterilization...
Solventum Earnings Call Transcript: Q1 2026
Q1 fiscal 2026 results exceeded expectations, with strong organic sales growth, margin expansion, and EPS outperformance. Transformation initiatives, portfolio optimization, and new product launches are driving momentum, while guidance for the year is maintained with EPS now expected at the high end of the range.
Solventum Earnings release: Q1 2026
Solventum released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Solventum Slides: Q1 2026
Solventum has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Solventum Quarterly report: Q1 2026
Solventum has published its Q1 2026 quarterly earnings report on May 5, 2026.
Solventum Shareholder letter: Q1 2026
Solventum has published a letter to shareholders covering Q1 2026, which was released on May 5, 2026.
Solventum Reports First Quarter 2026 Financial Results
Reported sales decreased (3.0)%; organic sales increased 2.1% Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing ra...
Peltz's Trian urges Solventum to rightsize costs, divest non-core businesses
Nelson Peltz's Trian Fund Management on Thursday called on Solventum to rightsize overhead costs, divest non-core businesses and improve capital allocation in its latest appeal for a performance tur...
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
Solventum's Spin-Out from 3M has Maximized Executive Compensation, Not Shareholder Value Outlines Three Initiatives to Improve Performance and Drive Value Creation at Solventum NEW YORK, April 30, 202...
Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026
ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close.
Solventum Proxy statement: Proxy filing
Solventum filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Solventum Proxy statement: Proxy filing
Solventum filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Solventum Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management outlined progress in transformation, with Separation halfway complete and full completion targeted by end of 2026. 2025 exceeded growth expectations, and 2026 guidance targets 2%-3% revenue growth and margin expansion despite tariff headwinds. Innovation and operational efficiency remain key drivers.
Solventum to Participate in the 2026 KeyBanc Healthcare Forum
ST. PAUL, Minn., March 11, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18...
Solventum beats quarterly estimates on strong demand for surgical products
Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.
Solventum Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year 2025 results, with 3.3% organic sales growth and margin expansion despite headwinds from tariffs and separation costs. 2026 guidance calls for 2%-3% organic growth, margin improvement, and continued portfolio optimization, supported by new product launches and cost-saving initiatives.
Solventum Shareholder letter: Q4 2025
Solventum has published a letter to shareholders covering Q4 2025, which was released on February 26, 2026.
Solventum Annual report: Q4 2025
Solventum has published its Q4 2025 annual report on February 26, 2026.
Solventum Earnings release: Q4 2025
Solventum released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Solventum Slides: Q4 2025
Solventum has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.